Replies to post #17329 on Positron Corporation (POSC)

[Budax]

With all due respect (and you may know more about this sort of thing that I), I do not see that a list of "measurables" (whatever that is, if not revenue) is the first thing big money is looking for, and I do not see that March 31 is of any significance. Some things that would be important are:

1) Finalization of the agreement with JDI.
2) FDA approval of Ruby-Fill
3) Bracco hitting on all cyclinders re: Cardiogen.

No. 3 may be the most likely to produce revenue (Attrius sales) fairly quickly.

None of these things is solely under POSC's control, but all are likely to occur in time.